JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma

  • 0Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China.
Frontiers in Oncology +

|

April 29, 2024

|

April 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Major pathological response (MPR) in lung squamous cell carcinoma (LUSC) patients receiving neoadjuvant chemoimmunotherapy (NCIO) is predicted by pre-treatment lymphocyte levels, tumor burden, N classification, radiographic response, pulmonary atelectasis, and PD-L1 expression. A nomogram model accurately predicts MPR, improving personalized treatment for LUSC.

Area Of Science

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Background

  • Major pathological response (MPR) is a key prognostic indicator for lung squamous cell carcinoma (LUSC) patients.
  • Predictors of MPR after neoadjuvant chemoimmunotherapy (NCIO) in LUSC remain incompletely understood.
  • Identifying these predictors is crucial for optimizing treatment strategies.

Purpose Of The Study

  • To investigate clinical factors influencing MPR achievement in potentially resectable LUSC patients undergoing NCIO.
  • To develop a predictive model for MPR to guide personalized therapy.

Main Methods

  • Retrospective analysis of 91 LUSC patients (Stage IIB-IIIC) who received NCIO and surgical resection.
  • Evaluation of pre-NCIO clinical, hematological, imaging, and PD-L1 expression data.
  • Development of a nomogram based on independent predictors of MPR.

Main Results

  • The MPR rate was 65%, with 43 cases of pathological complete remission (pCR).
  • Independent predictors of MPR included pre-treatment lymphocyte level, tumor burden, N classification, radiographic response, pulmonary atelectasis, and PD-L1 expression.
  • The developed nomogram achieved an AUC of 0.914 for MPR prediction.
  • MPR was associated with significantly improved disease-free survival (DFS).

Conclusions

  • Pre-treatment factors like lymphocyte level, tumor burden, N classification, radiographic response, pulmonary atelectasis, and PD-L1 expression are significant predictors of MPR in LUSC patients treated with NCIO.
  • The validated nomogram serves as a valuable tool for predicting MPR and personalizing treatment for potentially resectable LUSC.
  • Achieving MPR correlates with better long-term outcomes, emphasizing its importance in LUSC management.

Keywords: